KIR3DL2 and primary cutaneous T-cell non-Hodgkin lymphoma: IPH4102 is a first-in-class monoclonal antibody targeting KIR3DL2 that demonstrated a favorable safety profile and an encouraging ORR of 36.4% (43% in SS) in 44 patients with CTCL that had exposure to at least two prior systemic therapies [41].